Effect of Vitamin D Treatment in Primary Hyperparathyroidism
NCT ID: NCT00674154
Last Updated: 2013-11-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
46 participants
INTERVENTIONAL
2008-05-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D Repletion in Primary Hyperparathyroidism
NCT01306656
Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
NCT01329666
Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)
NCT00538720
Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
NCT00417612
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
NCT00754442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D group
Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
Cholecalciferol
2800 IE daily in 52 weeks
Placebo group
Placebo, two tablets daily in 52 weeks.
Cholecalciferol
2800 IE daily in 52 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cholecalciferol
2800 IE daily in 52 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* P-PTH \> 5 pmol/l
* P-OH25-vitamin D \< 80 nmol/l
Exclusion Criteria
* usage of Etalpha, Mimpara
* Cancer
* Sarcoidosis
* malabsorption
* pancreatitis
* alcohol abuse
* pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Rolighed, MD
Role: PRINCIPAL_INVESTIGATOR
Lars Rejnmark, MD,PhD,DrMed
Role: STUDY_DIRECTOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Osteoporoseklinikken, Aarhus University Hospital, THG
Aarhus C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bislev LS, Wamberg L, Rolighed L, Grove-Laugesen D, Rejnmark L. Effect of Daily Vitamin D3 Supplementation on Muscle Health: An Individual Participant Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1317-1327. doi: 10.1210/clinem/dgac004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHPT-20080011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.